Finder makes money from featured partners, but editorial opinions are our own.

How to buy Telix Pharmaceuticals (TLX) shares in Australia

Learn how to easily invest in Telix Pharmaceuticals shares.

Telix Pharmaceuticals is a biotechnology business based in Australia. Telix Pharmaceuticals shares (TLX) are listed on the Australian Securities Exchange (ASX) and all prices are in Australian dollars. Telix Pharmaceuticals has a trailing 12-month revenue of around $356.9 million. If you're looking to buy shares, check out the steps below.

How to buy shares in Telix Pharmaceuticals

  1. Compare share trading platforms. To buy shares listed in Australia, you'll need to sign up to a broker with access to the ASX. Our table can help you choose.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, such as your ID and tax file number. Fund your account with a bank transfer, PayPal or debit card.
  3. Search for Telix Pharmaceuticals . Find the share by name or ticker symbol: TLX. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Telix Pharmaceuticals reaches your desired price. Look into dollar-cost averaging to spread out your risk, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At today's price, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs.
  6. Check on your investment. Congratulations, you own a part of Telix Pharmaceuticals . Optimise your portfolio by tracking how your stock and the business performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that affect your stock.

Telix Pharmaceuticals stock price (ASX:TLX)

Use our graph to track the performance of TLX stocks over time.

Telix Pharmaceuticals shares at a glance

Information last updated 2023-11-25.
52-week range$5.825 - $12.79
50-day moving average $10.041
200-day moving average $9.8871
Target price$13.37
PE ratio 0
Dividend yield $0 (0%)
Earnings per share (TTM) $-0.34

Compare share trading platforms

The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.
1 - 6 of 6
Name Product Standard brokerage fee Inactivity fee Asset class
Finder AwardExclusive
US$10 per month if there’s been no log-in for 12 months
ASX shares, Global shares, US shares, ETFs
CFD service. Capital at risk.
Finder exclusive: Get 12 months of investment tracking app Delta PRO for free when you fund your eToro account (T&Cs apply).
Join the world’s biggest social trading network when you trade stocks, commodities and currencies from the one account.
IG Share Trading
Finder Award
IG Share Trading
ASX shares, Global shares, US shares, UK shares, ETFs
$0 brokerage for US and global shares plus get an active trader discount of $5 commission on Australian shares.
Enjoy some of the lowest brokerage fees on the market when trading Australian and international shares, plus get access to 24-hour customer support.
Moomoo Share Trading
ASX shares, Global shares, US shares, ETFs
Finder exclusive: Get an additional 30 days on top of the regular brokerage-free period for new accounts (see link for details). T&Cs apply.
Trade shares on the ASX, the US markets and buy ETFs with Moomoo. Plus join a community over 18 million investors.
CMC Invest
Finder Award
CMC Invest
ASX shares, Global shares, Options trading, US shares, mFunds, ETFs
$0 brokerage on global shares including US, UK and Japan markets.
Trade up to 35,000 products, including shares, crypto, ETFs and managed funds, with access to 15 major global and Australian stock exchanges. Plus, buy Aussie shares for $0 brokerage up to $1,000. (Limited to one buy order per stock per trading day).
ASX shares, Options trading, US shares, ETFs
Earn US$100 in cash vouchers when you fund your new account with US$2,000 until March 30, 2024. Plus, earn up to 5.3% p.a. interest on your US cash account (T&Cs apply).
Trade ASX and US stocks and US options, plus gain access to inbuilt news platforms and educational resources. You can also start trading for less with fractional shares.
Tiger Brokers
Tiger Brokers
ASX shares, Global shares, US shares, ETFs
Finder exclusive: Get 15 commission-free trades on US or ASX equities for the first 180 days and US$50 fractional shares when you deposit at least US$500. Plus, all new customers get 1 free trade per month for the first 12 months (T&Cs apply).
Get one brokerage-free trade per month for the first 12 months for US or ASX markets. T&Cs apply.

Is it a good time to buy Telix Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Telix Pharmaceuticals price performance over time

Historical closes compared with the last close of A$9.91

1 week (2023-11-24) 5.76%
1 month (2023-11-02) 8.90%
3 months (2023-09-01) -8.24%
6 months (2023-06-02) -8.41%
1 year (2022-12-02) 33.92%
2 years (2021-12-02) 53.17%
3 years (2020-12-02) 147.75%
5 years (2018-11-30) 1,368.15%

Is Telix Pharmaceuticals under- or over-valued?

Valuing Telix Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Telix Pharmaceuticals 's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Telix Pharmaceuticals 's EBITDA

Telix Pharmaceuticals 's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $26.2 million (£0.0 million).

The EBITDA is a measure of a Telix Pharmaceuticals 's overall financial performance and is widely used to measure a its profitability.

Telix Pharmaceuticals financials

Revenue TTM $356.9 million
Operating margin TTM 14.28%
Gross profit TTM $98.5 million
Return on assets TTM 5.18%
Return on equity TTM -52.36%
Profit margin -13.31%
Book value 0.239
Market capitalisation $3 billion

TTM: trailing 12 months

Telix Pharmaceuticals share dividends

We're not expecting Telix Pharmaceuticals to pay a dividend over the next 12 months.

Telix Pharmaceuticals share price volatility

Over the last 12 months, Telix Pharmaceuticals 's shares have ranged in value from as little as $5.825 up to $12.79. A popular way to gauge a stock's volatility is its "beta".

TLX.AU volatility(beta: 2.42)Avg. volatility(beta: 1.00)LowHigh

Beta measures a share's volatility in relation to the market. The market (AU average) beta is 1, while Telix Pharmaceuticals 's is 2.424. This would suggest that Telix Pharmaceuticals 's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Telix Pharmaceuticals overview

Telix Pharmaceuticals Limited, a radiopharmaceutical company, develops molecularly targeted radiation (MTR) products for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company focuses on developing diagnostic and therapeutic products using MTR. Its lead products include TLX591-CDx for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX250-CDx that is in Phase III clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX101-CDx for the diagnosis and treatment of glioblastoma (brain cancer); TLX66-CDx to treat bone marrow conditioning and rare diseases; TLX250, which is in Phase II clinical trials for the diagnosis and treatment of kidney cancer; TLX591, which is in Phase III clinical trials for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX101 that is in Phase I/II clinical trials for the treatment of glioblastoma (brain cancer); and TLX66, which is in Phase I/IIa clinical trials for the treatment of bone marrow conditioning and rare diseases. The company also develops TLX592, a prostate cancer therapy candidate for targeted alpha therapy; TLX591-Sx, a positron emission tomography (PET) tracer that delivers PET and fluorescent (optical) imaging; and TLX599-CDx, an investigational prostate cancer imaging agent that uses single photon emission computed tomography. It has a strategic license and commercial partnership with Mauna Kea Technologies and Lightpoint Medical to develop advanced image and radio-guided surgical technologies. The company was founded in 2015 and is headquartered in North Melbourne, Australia.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs comes with a higher risk of losing money rapidly due to leverage. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder only provides general advice and factual information, so consider your own circumstances, or seek advice before you decide to act on our content. By submitting a question, you're accepting our Terms of Use, Disclaimer & Privacy Policy and 6. Finder Group Privacy & Cookies Policy.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Go to site